Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lung Cancer Metastatic 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1Coronary Disease 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Atherosclerosis 1

Interventions

Exercise 2evolocumab 1Standard of Care 1Rosuvastatin Calcium 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Blood Specimen Collection 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Atherosclerosis × evolocumab × Clear all
NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Xinjiang Medical University

Phase 4 Unknown
620 enrolled

Neoplasms, Atherosclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡